-
Product Insights
Prometal Mine
The Prometal Mine is a iron ore mine in Brazil. It is currently in operation. Empower your strategies with our Prometal Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Sector Analysis
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Pulmonary Fibrosis (IPF) Marketed and Pipeline Drugs Market Report Overview IPF is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs). ILDs are characterized by damage to the lung parenchyma (the functional part of the lung that includes the alveolar tissue, bronchioles, bronchi, blood vessels, and interstitium) that occurs as a consequence of aberrant inflammation and fibrosis, thickening and scarring of the connective tissue. The development...
-
Company Profile
Liminal BioSciences Inc – Company Profile
Liminal BioSciences Inc (Liminal), formerly ProMetic Life Sciences Inc, is a biopharmaceutical company that focuses on plasma-derived therapeutics and small-molecule drug development. The company develops products for the treatment of fibrosis, including respiratory, liver, and kidney diseases. Liminal develops drug candidates based on two drug discovery platforms: small molecule therapeutics (PSMT), and plasma-derived therapeutics. The Company intends to capitalize on its drug discovery platform and knowledge base to build an early-stage drug portfolio. The company owns research and development facilities...
Add to Basket -
Product Insights
Primary Immune Deficiency (PID) Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Primary Immune Deficiency (PID) Global Clinical Trials Review, H1, 2018" provides an overview of Primary Immune Deficiency (PID) clinical trials scenario. This report provides top line data relating to the clinical trials on Primary Immune Deficiency (PID). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Emphysema Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Emphysema Global Clinical Trials Review, H2, 2017" provides an overview of Emphysema clinical trials scenario. This report provides top line data relating to the clinical trials on Emphysema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher
-
Product Insights
Liver Fibrosis Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis – Opportunity Analysis and Forecast to 2025
The IPF therapeutic market is currently dominated by the only two drugs that have gained marketing approval for IPF – Roche's Esbriet and Boehringer Ingelheim's Ofev. Esbriet was the first drug to gain approval for IPF in 2011 when it was approved for use in Europe, a full four years before rival Ofev. However, both gained approval into the largest IPF market of the US on the same day in October 2014. The top-selling drug in IPF in value terms...
-
Product Insights
Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016
GlobalData's clinical trial report, “Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2016" provides an overview of Systemic Sclerosis (Scleroderma) clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Sclerosis (Scleroderma). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...